1 / 43

#1003 Prostate Cancer Update

#1003 Prostate Cancer Update. October 5 to October 8 Robert R. Bahnson, MD Louis Levy Professor of Surgery Director, Division of Urology The Ohio State University Medical Center & The James Cancer Hospital and Solove Research Institute Eric A. Klein, MD

halle
Download Presentation

#1003 Prostate Cancer Update

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. #1003 Prostate Cancer Update October 5 to October 8 Robert R. Bahnson, MD Louis Levy Professor of Surgery Director, Division of Urology The Ohio State University Medical Center & The James Cancer Hospital and Solove Research Institute Eric A. Klein, MD Head, Section of the Urologic Oncology Cleveland Clinic Foundation

  2. Robert R. Bahnson, M.D.Louis Levy Professor of SurgeryDirector, Division of UrologyThe Ohio State University Medical CenterThe James Cancer Hospital and Solove Research Institute, Columbus, Ohio 1

  3. Profile Kevin • 42 year old white male • Father had prostate cancer • Healthy otherwise • Symptoms - Weakening urination stream - Frequent urination at night - Hesitancy when urinating - Dribbling of urination 2

  4. Profile Kevin • Evaluation - Digital rectal exam - Serum PSA determination 2A

  5. 3

  6. Prostate Cancer • Most commonly diagnosed cancer in adult men • More than 179,300 men diagnosed in 1999 • Estimated 37,000 will die of disease • Nearly 20 million males in U.S. forced to make important decisions regarding early detection • Controversy has prompted early detection guideline by the American Cancer Society and the American Urologic Assoc. advising a DRE and a serum PSA beginning at age 50 4

  7. Early Screening • Opponents point out that randomized trials have not demonstrated a survival benefit in screened patients • However, most agree that: - Digital Rectal Exam and Serum PSA have likely played a critical role in the downward prostate cancer stage migration seen in the last 10 years 5

  8. Guidelines • Who are men at high risk? - Those with a family history - All African American men, they should begin an early detection program at age 40 • Which men should undergo a biopsy? - Men with a life expectancy exceeding 10 years and a palpable abnormality on digital rectal exam - Men with a PSA greater than 10ng per ml 6

  9. Guidelines • In screening studies, nearly 3/4 of men will have a normal DRE and a PSA of less than 4 ng/ml • Only 15% of this population will have a cancer 7

  10. 8

  11. 9

  12. Recommendations • Men with a normal DRE and a PSA greater than 10ng per ml will harbor cancer greater than 50% of the time • Therefore, routine biopsy is suggested for men with a 10 year life expectancy if they have an abnormal DRE or a PSA greater than 10ng per ml 10

  13. Prostate-Specific Antigen • % Free PSA has emerged as the most clinically useful with the potential to provide: - Improvements in early detection - Staging - And Monitoring of prostate cancer 11

  14. 12

  15. Biopsy Procedures • Recent evidence suggests change in biopsy technique is needed to increase detection • Systemic parasaggital sextant biopsies are widely adopted as standard biopsy procedure • New literature suggests optimizing transrectal ultrasound-guided biopsy techniques 13

  16. Biopsy Procedures • Increasing number of biopsies increases likelihood of detecting cancers • Risk of finding cancer on repeat biopsy with an initial benign biopsy and an elevated serum PSA is 25% • Report by Dr. McCullough shows extended biopsy technique detects more cancers than standard sextant technique 14

  17. 15

  18. 16

  19. Summary Kevin • Serum PSA 1.5 ng/ml • Prostate slightly enlarged • No suspicious findings • Follow-Up: - Due to family history, annual prostate exam and testing is recommended 17

  20. Eric A Klein, M.D.Head, Section of Urologic OncologyThe Cleveland Clinic FoundationCleveland, Ohio 18

  21. Profile Simmons Brothers Brother #1 • 50 year old man • Saw family physician one year ago • Prostate was normal upon exam • PSA was slightly elevated • Prostate biopsy revealed a pre-cancerous condition, Prostatic Intra-epithelial Neoplasia or high-grade PIN • Subsequent biopsy confirmed presence of cancer • Underwent a radical prostectomy 19

  22. Profile Simmons Brothers Brother #2 • In family lounge, met twin brother • Recommended he be screened for prostate cancer • His biopsy showed high-grade PIN • Subsequent biopsy confirmed prostate cancer • Underwent a radical prostectomy • Genetic testing revealed brothers carried HPC1, which holds a higher risk for development of prostate cancer 20

  23. 20A

  24. 21

  25. Genes And Prostate Cancer • Susceptibility Genes - Influence development of cancer • Phenotypic Genes - Influence clinical behavior of cancer 22

  26. 23

  27. Major Susceptibility Locus ForProstate Cancer on Chromosome 1Suggested By A Genome-Wide Search • Susceptibility locus on long arm of chromosome 1 in certain families • Gene area designated as HPC1 • On-going intensive efforts to identify gene association with prostate cancer 24

  28. Prostate Cancer Susceptibility Genes • HPC1 - 1q24-35 - 9% of cases - Early age of onset - Many affected family members - ? African Americans - ? More advanced stage and grade - Structure and function unknown 25

  29. 26

  30. Evidence For A Prostate CancerSusceptibility Locus On TheX Chromosome • Three other reports that suggest three additional areas that predispose individuals to prostate cancer • HPCX which appeared in Nature in 1998 • Epidemiologic observations suggest that men with a brother affected with prostate cancer are more likely to get prostate cancer than those whose father was only affected • This suggests linkage with X chromosome 27

  31. Prostate Cancer Susceptibility Genes • HPCX - Xq27-28 - 16% of cases - Clinical features undescribed - Structure and function unknown - Not androgen receptor 28

  32. Predisposing Gene ForEarly-Onset Prostate Cancer,Localized On Chromosome 1q42.2-43 • French Study - Has demonstrated another susceptibility locus on chromosome 1 also on the long arm, but distal at Iq42 29

  33. Pcap Characteristics • 1q42.2-43 • Associated with early age of onset • Phenotype unknown • Structure and function unknown 30

  34. Evidence For A Rare ProstateCancer-Susceptibility LocusAt Chromosome 1p36 • University of Washington Study - Has identified a 4th susceptibility locus on chromosome 1, on the short arm at 1 p36 31

  35. CAPB Characteristics • Chromosome 1p36 • Frequent LOH in CNS tumors • Not linked to age of onset • Linked to FH of CNS tumors • Clinical behavior unknown • Probably rare 32

  36. Genes And Prostate Cancer • Susceptibility Genes - HPC1 - HPCX - Others likely - 4q, 5p, 7p, 13q • Phenotypic Genes - Androgen Receptor - “Family history” gene - Androgen metabolism genes 33

  37. 34

  38. 35

  39. 36

  40. 37

  41. 38

  42. 39

  43. NEXT WEEK #1004 Evaluation & Management of Back Pain October 12 to October 15 Brian Bowyer, MD Associate Professor of Physical Medicine and Rehabilitation Department of Physical Medicine and Rehabilitation The Ohio State University Medical Center Lawrence J. Mervis, M.D. Clinical Associate Professor of Surgery The Ohio State University Medical Center and James Cancer Hospital and Solove Research Institute Columbus, Ohio

More Related